|
Edward Kavalerchik |
Angiocrine Bioscience, Inc. |
Phase 1 |
Recruiting |
9 |
|
|
Edward Kavalerchik |
Angiocrine Bioscience, Inc. |
Phase 1 |
Recruiting |
24 |
|
|
David Williams |
Boston Children's Hospital |
Phase 2 |
Launching |
N/A |
|
|
Krystof Bankiewicz |
Brain Neurotherapy Bio |
Phase 1 |
Recruiting |
12 |
|
|
Ralph Kern |
BrainStorm Cell Therapeutics |
Phase 3 |
Completed |
261 |
|
|
William Sietsema |
Caladrius Biosciences |
Phase 2 |
Completed |
113 |
|
|
Robert Dillman |
Caladrius Biosciences |
Phase 3 |
Closed |
4 |
|
|
Kristen Johnson |
Calibr |
Phase 1 |
Completed |
60 |
|
|
Geoff Symonds |
Calimmune, Inc. |
Phase 1/2 |
Completed |
13 |
|
|
Rachel Smith |
Capricor, Inc |
Phase 2 |
Closed |
156 |
|
|
Linda Marban |
Capricor, Inc |
Phase 2 |
Completed |
25 |
|
|
Michael Lewis |
Cedars-Sinai Medical Center |
Phase 1/2 |
Recruiting |
26 |
|
|
Clive Svendsen |
Cedars-Sinai Medical Center |
Phase 1/2 |
Completed |
18 |
|
|
Clive Svendsen |
Cedars-Sinai Medical Center |
Phase 1 |
Recruiting |
16 |
|
|
Xiaokui Zhang |
Celularity Inc |
Phase 1/2 |
Recruiting |
86 |
|
|
Michael Pulsipher |
Children's Hospital of Los Angeles |
Phase 1/2 |
Active, not recruiting |
60 |
|
|
Christine Brown |
City of Hope, Beckman Research Institute |
Phase 1 |
Recruiting |
92 |
|
|
Joseph Rosenthal |
City of Hope, Beckman Research Institute |
Phase 1 |
Active, not recruiting |
6 |
|
|
John Zaia |
City of Hope, Beckman Research Institute |
Phase 1 |
Active, not recruiting |
12 |
|
|
Saul Priceman |
City of Hope, Beckman Research Institute |
Phase 1 |
Recruiting |
39 |
|
|
John Zaia |
City of Hope, Beckman Research Institute |
Phase 1 |
Launching |
N/A |
|
|
Pierre Caudrelier |
ExCellThera Inc. |
Phase 1 |
Launching |
N/A |
|
- Leukemia, Acute Myeloid (AML)
|
Mark Chao |
Forty Seven Inc. |
Phase 1 |
Recruiting |
287 |
|
|
Mark Chao |
Forty Seven Inc. |
Phase 1/2 |
Completed |
78 |
|
|
Jane Lebkowski |
Geron Corporation |
Phase 1 |
Completed |
5 |
|
|
Jeffrey Lawson |
Humacyte, Inc. |
Phase 3 |
Active, not recruiting |
355 |
|
|
Jeffrey Lawson |
Humacyte, Inc. |
Phase 3 |
Recruiting |
240 |
|
|
Anthony Gringeri |
ImmunoCellular Therapeutics |
Phase 3 |
Suspended |
414 |
|
|
Henry Klassen |
jCyte, Inc |
Phase 2 |
Active, not recruiting |
84 |
|
|
Henry Klassen |
jCyte, Inc |
Phase 2 |
Active, not recruiting |
84 |
|
|
Francois Binette |
Lineage Cell Therapeutics Inc. |
Phase 1/2 |
Completed |
25 |
|
|
Daniel Brennan |
Medeor Therapeutics, Inc. |
Phase 3 |
Recruiting |
30 |
|
- Leukemia, Acute Myeloid (AML)
|
Colleen Delaney |
Nohla Therapeutics Inc |
Phase 2 |
Closed |
146 |
|
|
Matthew Spear |
Poseida Therapeutics, Inc. |
Phase 1 |
Recruiting |
220 |
|
|
Gayatri Rao |
Rocket Pharmaceuticals, Inc. |
Phase 1 |
Recruiting |
2 |
|
- Leukocyte Adhesion Deficiency
|
Kinnari Patel |
Rocket Pharmaceuticals, Inc. |
Phase 1/2 |
Recruiting |
9 |
|
|
Bijan Nejadnik |
SanBio, Inc. |
Phase 2 |
Completed |
163 |
|
|
Bettina Cockroft |
Sangamo BioSciences, Inc. |
Phase 1/2 |
Active, not recruiting |
6 |
|
|
Stephen Gottschalk |
St. Jude Children's Research Hospital |
Phase 1/2 |
Recruiting |
28 |
|
|
Samuel Strober |
Stanford University |
Phase 1 |
Active, not recruiting |
15 |
|
|
Crystal Mackall |
Stanford University |
Phase 1 |
Recruiting |
57 |
|
|
Everett Meyer |
Stanford University |
Phase 1 |
Recruiting |
22 |
|
|
Judith Shizuru |
Stanford University |
Phase 1/2 |
Recruiting |
42 |
|
|
Irving Weissman |
Stanford University |
Phase 1 |
Completed |
88 |
|
|
Diana Farmer |
University of California, Davis |
Phase 1 |
Not yet recruiting |
35 |
|
|
Vicki Wheelock |
University of California, Davis |
Phase 1/2 |
Completed |
29 |
|
|
Mehrdad Abedi |
University of California, Davis |
Phase 1/2 |
Recruiting |
18 |
|
|
Nancy Lane |
University of California, Davis |
Phase 1/2 |
Active, not recruiting |
59 |
|
|
Henry Klassen |
University of California, Irvine |
Phase 1/2 |
Completed |
28 |
|
|
Antoni Ribas |
University of California, Los Angeles |
Phase 1 |
Recruiting |
12 |
|
- X-linked Chronic Granulomatous Disease
|
Donald Kohn |
University of California, Los Angeles |
Phase 1/2 |
Active, not recruiting |
10 |
|
|
Donald Kohn |
University of California, Los Angeles |
Phase 1 |
Recruiting |
6 |
|
|
Steven Dubinett |
University of California, Los Angeles |
Phase 1 |
Recruiting |
36 |
|
|
Donald Kohn |
University of California, Los Angeles |
Phase 2 |
Completed |
10 |
|
|
Theodore Nowicki |
University of California, Los Angeles |
Phase 1 |
Recruiting |
12 |
|
|
Sophie Deng |
University of California, Los Angeles |
Phase 1 |
Recruiting |
20 |
|
|
Dennis Slamon |
University of California, Los Angeles |
Phase 1 |
Active, not recruiting |
48 |
|
|
Thomas Kipps |
University of California, San Diego |
Phase 1/2 |
Recruiting |
156 |
|
|
Stephanie Cherqui |
University of California, San Diego |
Phase 1/2 |
Recruiting |
6 |
|
|
Thomas Kipps |
University of California, San Diego |
Phase 1 |
Completed |
26 |
|
|
Michael Matthay |
University of California, San Francisco |
Phase 2 |
Recruiting |
120 |
|
|
Steven Deeks |
University of California, San Francisco |
Phase 1/2 |
Launching |
N/A |
|
- Severe Combined Immunodeficiency, Artemis deficient (ART-SCID)
|
Morton Cowan |
University of California, San Francisco |
Phase 1 |
Recruiting |
15 |
|
|
Tippi MacKenzie |
University of California, San Francisco |
Phase 1 |
Recruiting |
10 |
|
|
Peter Stock |
University of California, San Francisco |
Phase 1/2 |
Recruiting |
8 |
|
|
Mark Humayun |
University of Southern California |
Phase 1 |
Active, not recruiting |
16 |
|
|
Howard Foyt |
ViaCyte, Inc. |
Phase 1/2 |
Active, not recruiting |
69 |
|
|
Howard Foyt |
ViaCyte, Inc. |
Phase 1/2 |
Recruiting |
75 |
|